Table 2.
The geometric mean concentration (GMC) of anti-RBD antibody after a single dose of the AZD1222 vaccine (weeks)
| Time elapsed from first dose of AZD1222 (weeks) | Sample (N) | Geometric mean concentration of anti-SARS-CoV-2 antibody concentration (95%CI) (BAU/mL) | Geometric mean ratio (95%CI)* |
|---|---|---|---|
| Baseline level | 794 | < 0.4 | |
| 3 | 118 | 14.80 (10.81, 20.23) | Reference |
| 4 | 120 | 27.23 (20.84,35.56) | 1.79 (1.30, 2.48) |
| 5 | 123 | 46.56 (37.07,58.34) | 3.05 (2.22, 4.18) |
| 6 | 251 | 48.87 (41.50, 57.54) | 3.79 (2.86, 5.01) |
| 7 | 63 | 47.97 (37.41, 61.52) | 4.78 (3.21, 7.11) |
| 8 | 1 | 65.48 | 4.28 (0.36, 50.58) |
| 9 | 66 | 56.75 (42.46, 75.86) | 4.20 (2.88, 6.12) |
| 10 | 382 | 65.16 (58.48, 72.44) | 4.47 (3.43, 5.81) |
| 11 | 31 | 83.75 (55.98, 125.31) | 5.58 (3.41, 9.16) |
*adjust with age, sex, underlying disease, GMR; geometric mean ratio, 95%CI; 95% confidence interval.